PROVECTUS BIOPHARMS (PVCT) earnings
PVCT earnings moved a median of +0.69% by the close. Quarterly and annual PVCT reports and results, each read against the price at its own news timestamp. Back to the PVCT overview →
17 measured PVCT earnings events.
Where these PVCT earnings landedvs 16 measured PVCT earnings reactions
| Middle 50% of PVCT earnings reactions | -2.81% to +2.03% |
|---|---|
| Median reaction (to close) | +0.69% |
| Measured reactions | 16 |
Point-in-time · zero look-ahead
Half of the 16 PVCT earnings events with a measured close landed between -2.81% and +2.03%; 63% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q PROVECTUS BIOPHARMACEUTI For: Jun 30 | SEC filing · Form 10-Q | — | -3.61% | |
| Form 10-Q PROVECTUS BIOPHARMACEUTI For: Mar 31 | SEC filing · Form 10-Q | — | +2.04% | |
| Form 10-K PROVECTUS BIOPHARMACEUTI For: Dec 31 | SEC filing · Form 10-K | +0.00% | -6.81% | |
| Form 10-Q PROVECTUS BIOPHARMACEUTI For: Sep 30 | SEC filing · Form 10-Q | — | — | |
| Form 10-Q PROVECTUS BIOPHARMACEUTI For: Jun 30 | SEC filing · Form 10-Q | — | +0.00% | |
| Form 10-K/A PROVECTUS BIOPHARMACEUTI For: Dec 31 | SEC filing · Form 10-K | — | +1.17% | |
| Form 10-Q PROVECTUS BIOPHARMACEUTI For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +0.36% | |
| Form 10-K PROVECTUS BIOPHARMACEUTI For: Dec 31 | SEC filing · Form 10-K | +0.00% | +5.31% | |
| Form 10-Q PROVECTUS BIOPHARMACEUTI For: Sep 30 | SEC filing · Form 10-Q | — | +2.02% | |
| Provectus Biopharmaceuticals Announces Investor Webinar for Fourth Quarter 2024 Conference Call | Press release | +0.65% | +0.23% | |
| Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call | Press release | +0.00% | -4.70% | |
| Form 10-Q PROVECTUS BIOPHARMACEUTI For: Jun 30 | SEC filing · Form 10-Q | — | +1.01% | |
| Form 10-Q PROVECTUS BIOPHARMACEUTI For: Mar 31 | SEC filing · Form 10-Q | — | +1.38% | |
| Form 10-K/A PROVECTUS BIOPHARMACEUTI For: Dec 31 | SEC filing · Form 10-K | — | +2.08% | |
| Form 10-K PROVECTUS BIOPHARMACEUTI For: Dec 31 | SEC filing · Form 10-K | — | -3.71% | |
| Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call | Press release | +0.00% | +4.10% | |
| Form 10-Q PROVECTUS BIOPHARMACEUTI For: Sep 30 | SEC filing · Form 10-Q | — | -2.54% |
Keep exploring
More PVCT: analyst actions → · SEC filings → · PVCT overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| INNOVATE BIOPHARMACEUTICALS (INNT) | 220 | -0.77% | 38% |
| OWC PHARMS RESEARCH CORP (OWCP) | 220 | +0.09% | 52% |
| TG Therapeutics, Inc. (TGTX) | 220 | -0.06% | 47% |
| Lipocine Inc. (LPCN) | 219 | +0.34% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.